Tobin Schilke - 10 Mar 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Financial Officer
Signature
Tobin Schilke
Issuer symbol
CRNX
Transactions as of
10 Mar 2025
Net transactions value
$0
Form type
4
Filing time
11 Mar 2025, 16:30:06 UTC
Previous filing
05 Mar 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +52,000 $0.000000 52,000 10 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 10 Mar 2025 Common Stock 80,000 $33.75 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2026.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2026, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.